← Back to headlines
Patient Deaths in China Trials Spur US Demand for FDA Scrutiny
Patient deaths occurring in clinical trials in China have prompted demands from the United States for increased scrutiny from the FDA.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
